Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer

Lung Cancer

Volumn 86, Issue 3, 2014, Pages 358-362

  Kourelis, Taxiarchis V ^a   Wysokinska, Ewa M ^a   Wang, Yi ^a,b   Yang, Ping ^a   Mansfield, Aaron S ^a   Tafur, Alfonso J ^c  

^a MAYO CLINIC   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c Department of Psychiatry   (United States)

Author keywords

Incidence; Lung neoplasms; Prognosis; Survival; Thrombosis; Venous thromboembolism

Indexed keywords

BEVACIZUMAB; ERYTHROPOIETIN; ESTROGEN; GESTAGEN; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CHARLSON COMORBIDITY INDEX; DEEP VEIN THROMBOSIS; EARLY VENOUS THROMBOEMBOLISM; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMALL CELL LUNG CANCER; THROMBOEMBOLISM; VENOUS STASIS; VENOUS THROMBOEMBOLISM; COMPLICATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SMALL CELL LUNG CARCINOMA; VENOUS THROMBOEMBOLISM;

EID: 84961291398     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.10.003     Document Type: Article

References (29)

1. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007, March (5):632-634.
2. Trujillo-Santos J., Casas J.M., Casado I., Samperiz A.L., Quintavalla R., Sahuquillo J.C., et al. Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Thromb Res 2011, 127(February (Suppl. 3)):S1-S4.
3. Heit J.A., O'Fallon W.M., Petterson T.M., Lohse C.M., Silverstein M.D., Mohr D.N., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002, 162(June):1245-1248.
4. Paneesha S., McManus A., Arya R., Scriven N., Farren T., Nokes T., et al. Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost 2010, February (103):338-343.
5. Hicks L.K., Cheung M.C., Ding K., Hasan B., Seymour L., Le Maitre A., et al. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer 2009, 115(December):5516-5525.
6. Anderson L.A., Moore S.C., Gridley G., Stone B.J., Landgren O. Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans. Leuk Lymphoma 2011, 52(May):764-770.
7. Phan M., John S., Casanegra A.I., Rathbun S., Mansfield A., Stoner J.A., et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. J Thromb Thrombolysis 2013, 38(2):241-249.
8. Verso M., Gussoni G., Agnelli G. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost 2010, 8(July):1649-1651.
9. Haas S.K., Freund M., Heigener D., Heilmann L., Kemkes-Matthes B., von Tempelhoff G.F., et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012, 18(March-April):159-165.
10. Farge D., Debourdeau P., Beckers M., Baglin C., Bauersachs R.M., Brenner B., et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013, 11(January):56-70.
11. Kirwan C.C., McDowell G., McCollum C.N., Byrne G.J. Incidence of venous thromboembolism during chemotherapy for breast cancer: impact on cancer outcome. Anticancer Res 2011, 31(6):2383-2388.
12. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
13. Aapro M., Scherhag A., Burger H.U. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 2008, 99(July):14-22.
14. Peragallo Urrutia R., Coeytaux R.R., McBroom A.J., Gierisch J.M., Havrilesky L.J., Moorman P.G., et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol 2013, 122(August):380-389.
15. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90(September):1371-1388.
16. Hurwitz H.I., Saltz L.B., Van Cutsem E., Cassidy J., Wiedemann J., Sirzen F., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011, 29(May):1757-1764.
17. Connolly G.C., Dalal M., Lin J., Khorana A.A. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer 2012, 78(December):253-258.
18. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2(August):706-714.
19. Chew H.K., Davies A.M., Wun T., Harvey D., Zhou H., White R.H. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008, 6(April):601-608.
20. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007, 110(November):2339-2346.
21. Zhang Y., Yang Y., Chen W., Guo L., Liang L., Zhai Z., et al. Prevalence and associations of venous thromboembolism in patients with newly diagnosed lung cancer. Chest 2014, 146(September (3)):650-658.
22. Khorana A.A., Dalal M., Lin J., Connolly G.C. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013, 119(February):648-655.
23. Metcalf R.L., Fry D.J., Swindell R., McGurk A., Clamp A.R., Jayson G.C., et al. Thrombosis in ovarian cancer: a case control study. Br J Cancer 2014, 110(March):1118-1124.
24. Tormoen G.W., Haley K.M., Levine R.L., McCarty O.J. Do circulating tumor cells play a role in coagulation and thrombosis?. Front Oncol 2012, 2:115.
25. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000, 160(March):809-815.
26. Blom J.W., Vanderschoot J.P., Oostindier M.J., Osanto S., van der Meer F.J., Rosendaal F.R. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006, 4(March):529-535.
27. Donadini M.P., Dentali F., Squizzato A., Guasti L., Ageno W. Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data. Intern Emerg Med 2014, 9(June (4)):375-384.
28. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7(September):719-727.
29. Weir H.K., Thun M.J., Hankey B.F., Ries L.A., Howe H.L., Wingo P.A., et al. Annual report to the nation on the status of cancer: 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003, 95(17):1276-1299.